Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992329 · ClinicalTrials.gov registry record · Phase 1
Impact of Formulation on Ciprofloxacin Oral Absorption
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00992329 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 16 participants.
The verdict
NCT00992329, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this research is to see if certain tablet formulation factors affect oral drug absorption. Medications taken by mouth, such as tablets, need to be absorbed into the body in order to do any good. Tablets contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the tablet, and the way in which the tablet is manufactured, both can impact how much drug is absorbed into the body. That is, tablet formulation factors can cause a tablet to be effective or not effective. Tablets in this research contain the drug ciprofloxacin hydrochloride. Ciprofloxacin is an antibiotic to treat infections, such as lung infections. This drug is being used since it has low water solubility and is probably sensitive to tablet formulation factors.
Interventions
- DRUG ciprofloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992329
The ClinicalTrials.gov registry entry for NCT00992329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ciprofloxacin is the first listed.
NCT00992329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992329 about?
NCT00992329 is a clinical study titled "Impact of Formulation on Ciprofloxacin Oral Absorption". The purpose of this research is to see if certain tablet formulation factors affect oral drug absorption. Medications taken by mouth, such as tablets, need to be absorbed into the body in order to do any good. Tablets contain a drug, but also contain non-drug ingredients that are called excipients o...
What is the current status of trial NCT00992329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00992329?
The interventions under investigation include: ciprofloxacin (DRUG).
Who is sponsoring clinical trial NCT00992329?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.